



Published in final edited form as:

Nat Med. 2012 December ; 18(12): 1797–1804. doi:10.1038/nm.2996.

## Abnormal development of NG2+PDGFR $\alpha$ + neural progenitor cells leads to neonatal hydrocephalus in a ciliopathy mouse model

Calvin S. Carter<sup>1,\*</sup>, Timothy W. Vogel<sup>2,\*</sup>, Qihong Zhang<sup>3,9</sup>, Seongjin Seo<sup>4,9</sup>, Ruth E. Swiderski<sup>3,9</sup>, Thomas O. Moninger<sup>8</sup>, Martin D. Cassell<sup>5</sup>, Daniel R. Thedens<sup>6</sup>, Kim M. Keppler-Noreuil<sup>3</sup>, Peggy Nopoulos<sup>7</sup>, Darryl Y. Nishimura<sup>3</sup>, Charles C. Searby<sup>3,9</sup>, Kevin Bugge<sup>3,9</sup>, and Val C. Sheffield<sup>3,9</sup>

<sup>1</sup>Graduate Program in Neuroscience, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>2</sup>Department of Neurosurgery, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>3</sup>Department of Pediatrics, Division of Medical Genetics, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>4</sup>Department of Ophthalmology, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>5</sup>Department of Anatomy and Cell Biology, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>6</sup>Department of Radiology, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>7</sup>Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>8</sup>Central Microscopy Research Facilities, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

<sup>9</sup> Howard Hughes Medical Institute, University of Iowa Carver College of Medicine, Iowa, IA 52242, USA.

### Abstract

Hydrocephalus is a common neurological disorder leading to expansion of the cerebral ventricles and is associated with significant morbidity and mortality. Most neonatal cases are of unknown etiology and are likely to display complex inheritance involving multiple genes and environmental

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

**Corresponding author and reprint requests:** Val C. Sheffield, M.D., Ph.D., Howard Hughes Medical Institute, University of Iowa Carver College of Medicine, Iowa City, Iowa, 52242. Telephone # (319)-355-7311 Fax # (319)-353-6605.

\*Equal author contribution.

**Author Contributions.** C.S.C., T.W.V. and Q.Z. conceived of the project, designed, and performed experiments, coordinated collaborations, and wrote the manuscript. S.S. contributed to the experimental design and manuscript revisions. R.E.S. and M.C. performed TEM, CSF collection and dye injection experiments and revised the manuscript. T.O.M. coordinated microscopic experiments. K.M.K. and P.N. provided and analyzed human MRIs. D.R.T. performed magnetic resonance imaging for all mice. D.Y.N. and C.C.S. designed and developed the *Bbs1* mouse model used in this experiment. K.B. coordinated mouse genotyping and mating. V.C.S. initiated the project, contributed ideas, analyzed and interpreted the results, and helped write the manuscript.

factors. Identifying molecular mechanisms for neonatal hydrocephalus and developing non-invasive treatment modalities are high priorities. Here we employ a hydrocephalic mouse model of the human ciliopathy Bardet-Biedl Syndrome (BBS) and identify a role for neural progenitors in the pathogenesis of neonatal hydrocephalus. We found that hydrocephalus in this mouse model is caused by aberrant PDGFR $\alpha$  signaling, resulting in increased apoptosis and impaired proliferation of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> neural progenitors. Targeting this pathway with lithium treatment rescued NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> progenitor cell proliferation in BBS mutant mice, reducing ventricular volume. Our findings demonstrate that neural progenitors are critical in the pathogenesis of neonatal hydrocephalus and we identify novel therapeutic targets for this common neurological disorder.

## Keywords

hydrocephalus; Bardet-Biedl Syndrome; ciliopathy; neural progenitor cell; NG2; PDGFR $\alpha$ ; AKT; GSK3 $\beta$ ; lithium; apoptosis

Neonatal hydrocephalus is a common disorder affecting the human nervous system with an estimated incidence of 1 to 3 per 1,000 live births<sup>1-4</sup> creating a healthcare burden of 2 billion dollars annually<sup>5,6</sup>. Hydrocephalus leads to the expansion of cerebral ventricles and is associated with significant morbidity and mortality<sup>7-9</sup>. Neonatal hydrocephalus remains an understudied disease despite being a common developmental anomaly<sup>10</sup>. Neonatal hydrocephalus has multiple causes including obstruction of cerebrospinal fluid (CSF) flow and CSF overproduction; however, a significant portion of neonatal hydrocephalus is idiopathic in nature<sup>9-16</sup>. Current therapies rely on invasive procedures associated with high failure and complication rates making the identification of molecular mechanisms underlying neonatal hydrocephalus a high priority for the medical community<sup>3,9,11,17,18</sup>.

Recently, mouse models with impaired cilia function have provided insight into mechanisms involved in hydrocephalus occurring in the absence of obstruction, a condition known as communicating hydrocephalus<sup>10,13,14,19,20</sup>. Mutations in genes that disrupt ependymal motile cilia structure and function hinder ependymal motile cilia beat frequency and CSF flow leading to the development of hydrocephalus<sup>13,14,19,20</sup>. Non-motile cilia known as primary cilia, extend from the surface of nearly all cell types. Primary cilia serve as sensory antennae facilitating many signaling pathways including Wnt<sup>21</sup>, sonic hedgehog (Shh)<sup>22,23</sup>, and platelet derived growth factor receptor alpha (PDGFR $\alpha$ )<sup>24</sup> enabling cells to respond to developmental cues in several sites of neurogenesis in the central nervous system (CNS) including the periventricular regions<sup>25</sup>. These non-motile cilia are required for normal development of neural progenitor cells (NPCs)<sup>26,27</sup>.

Recent findings have demonstrated that ependymal motile cilia and CSF flow are required for normal development of NPCs suggesting an intimate link between the ventricular system and neural development<sup>28</sup>. The close proximity of NPCs to the periventricular regions suggests that these cells play a role in maintaining the integrity of the ventricular system<sup>25,29</sup>. However, a role for NPCs in the pathophysiology of hydrocephalus has not been studied. In this study we investigated whether abnormal signaling through primary cilia in NPCs may contribute to the genesis of neonatal hydrocephalus. To test this hypothesis, we utilize a mouse model of a genetically heterogeneous human disorder known as Bardet-

Biedl syndrome (BBS) caused by mutations in one or more of 17 genes, seven of which (BBS 1,2,4,5,7,8 and 9) form a complex known as the BBSome<sup>30</sup>. The cardinal features of BBS include retinal degeneration, obesity and cognitive delay<sup>19</sup>. Some BBS patients have enlarged cerebral ventricles and BBS mouse models display communicating hydrocephalus<sup>19,31,32</sup>. Here we demonstrate that abnormal development of NPCs specifically expressing the chondroitin sulfate proteoglycan NG2 and PDGFR $\alpha$  leads to the development of neonatal ventriculomegaly in BBS mice. Our findings identify a novel mechanism underlying hydrocephalus and provide a therapeutic target for treatment.

## RESULTS

### BBS mutant mice develop neonatal hydrocephalus

We have previously shown that BBS mutant mice homozygous for the most common human BBS mutation (*Bbs1*<sup>M390R/M390R</sup>) develop ventricular dilatation similar to that reported in human BBS patients<sup>19,31,32</sup> (Fig. 1a,b). Ventriculomegaly in *Bbs1*<sup>M390R/M390R</sup> mice is fully penetrant and is accompanied by neurological deficits, similar to patients with hydrocephalus<sup>3,9,19,31,32</sup>. We employ the term hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice to describe the ventriculomegaly as previously reported in other mouse models<sup>4,9,10,14–16,20</sup>.

We first examined the time of onset of hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> brains by examining hematoxylin and eosin (H&E) stained sections. Dilation of the lateral ventricles begins at P0-P3 in *Bbs1*<sup>M390R/M390R</sup> mice (Fig. 1c,d). Importantly, this timing is prior to the maturation of ependymal motile cilia, which occurs from P5–P10<sup>10,13,14</sup> suggesting that the onset of hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice occurs independently of ependymal motile cilia function (Fig. 1e).

### Increased apoptosis and reduced proliferation in the brains of *Bbs1*<sup>M390R/M390R</sup> mice

Next we studied whether known causes of hydrocephalus contribute to the phenotype observed in *Bbs1*<sup>M390R/M390R</sup> mice. Evan's blue dye injection showed no evidence of obstructive hydrocephalus (Supplementary Fig. 1). We found no evidence of excess CSF production in *Bbs1*<sup>M390R/M390R</sup> mice based on normal choroid plexus ultrastructure and normal CSF ion concentrations (Supplementary Fig. 1).

Consequently, we sought to identify other potential mechanisms that may contribute to the early development of the communicating hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice. Previous work has shown that these mice have a small corpus striatum<sup>19</sup>. Moreover, BBS patients have reduced white and gray matter in periventricular regions<sup>31,32</sup>. Therefore, we examined apoptosis and cell proliferation in the periventricular regions in *Bbs1*<sup>M390R/M390R</sup> mice to determine whether cell loss contributes to the pathophysiology of neonatal hydrocephalus. Immunofluorescent analysis using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), a marker of apoptotic cells and Bromodeoxy-Uridine (BrdU), a marker of proliferating cells, identified TUNEL<sup>+</sup> cells adjacent to the lateral ventricles and BrdU<sup>+</sup> cells in the subventricular zone (SVZ) in both wild-type (WT) and *Bbs1*<sup>M390R/M390R</sup> mice (Fig. 2a). Quantitation revealed that *Bbs1*<sup>M390R/M390R</sup> mice have a two-fold increase in

apoptosis and a 50% reduction in cell proliferation in the periventricular regions at P3 and P7 relative to WT mice (Fig. 2b).

### Abnormal development of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> neural progenitor cells in *Bbs1*<sup>M390R/M390R</sup> mice

We next investigated the cell type responsible for the imbalance in apoptosis and cell proliferation by examining a number of markers of NPCs, neurons, and glia. Using immunofluorescence, we double stained coronal brain slices from WT and *Bbs1*<sup>M390R/M390R</sup> neonates with either TUNEL or BrdU and markers of these major cell types. We found no significant differences between WT and *Bbs1*<sup>M390R/M390R</sup> brains in the number of TUNEL labeled cells also staining positive for markers of developing (Nestin) and mature neurons (NeuN), astrocytes (GFAP) and oligodendrocytes (O4, refs. <sup>33–35</sup>; Fig. 3a and Supplementary Fig. 2). Notably, we observed that nearly all TUNEL<sup>+</sup> cells in both WT and *Bbs1*<sup>M390R/M390R</sup> mice expressed NG2 and PDGFR $\alpha$ , two markers of oligodendrocyte precursor cells (OLPs)<sup>36–40</sup>. Quantification revealed that a larger proportion (>two-fold) of TUNEL labeled cells are also NG2<sup>+</sup> and PDGFR $\alpha$ <sup>+</sup> in *Bbs1*<sup>M390R/M390R</sup> mice compared to WT (Fig. 3a). NG2 and PDGFR $\alpha$  have been previously shown to mark a particular class of OLPs expressed early in the lineage that are termed NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs<sup>36–40</sup>. We also examined Olig2, a sonic hedgehog induced basic helix loop helix transcription factor expressed later in the oligodendrocytic lineage than NG2 and PDGFR $\alpha$ , which are both rapidly downregulated when differentiation to oligodendrocytes occurs<sup>36–39</sup>. We found no significant overlap between TUNEL<sup>+</sup> and Olig2<sup>+</sup> cells indicating that in both WT and *Bbs1*<sup>M390R/M390R</sup> mice more mature OLPs and oligodendrocytes are not undergoing apoptosis (Fig. 3a). Quantitation revealed no significant difference between WT and *Bbs1*<sup>M390R/M390R</sup> mice in the number of TUNEL<sup>+</sup> cells also labeled with Olig2 ( $P=0.29$ , Fig. 3a)

Next we investigated the identity of the proliferating cells. We observed that NG2<sup>+</sup>, PDGFR $\alpha$ <sup>+</sup> and Olig2<sup>+</sup> OLPs constituted a large portion of BrdU<sup>+</sup> cells in the SVZ of WT mice (Fig. 3b). However, in *Bbs1*<sup>M390R/M390R</sup> brains there was approximately 50% fewer BrdU labeled NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> cells in the SVZ (Fig. 3b). WT and BBS mutant mice did not differ in the number of Olig2<sup>+</sup> cells undergoing cell proliferation (BrdU<sup>+</sup>) ( $P=0.39$ , Fig. 3b). There was also no significant difference between WT and *Bbs1*<sup>M390R/M390R</sup> mice with respect to the other cell markers examined (Fig. 3b and Supplementary Fig. 2).

We then quantified the number of NG2<sup>+</sup>, PDGFR $\alpha$ <sup>+</sup> and Olig2<sup>+</sup> cells within the SVZ in order to determine the effect of impaired survival and proliferation in these precursor cells. We found significantly fewer of these cell populations in the SVZ of *Bbs1*<sup>M390R/M390R</sup> brains relative to WT (Supplementary Fig. 3). These results demonstrate that NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs display increased apoptosis and reduced proliferation leading to reduced OLP populations in the brains of *Bbs1*<sup>M390R/M390R</sup> mice.

### Conditional knockout of *Bbs1* in PDGFR $\alpha$ <sup>+</sup> cells leads to neonatal hydrocephalus

To confirm the involvement of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs in the genesis of neonatal hydrocephalus in BBS, we generated conditional knockout mice lacking *Bbs1* in PDGFR $\alpha$  expressing NPCs (*Bbs1*<sup>loxP/loxP</sup> × *PDGFR $\alpha$* <sup>Cre</sup>; *Bbs1*<sup>CKO</sup>). *Bbs1* mRNA was almost

completely absent in cortex and significantly reduced in the hypothalamus of *Bbs1*<sup>CKO</sup> mice; moreover, Cre was expressed in NG2<sup>+</sup>, PDGFR $\alpha$ <sup>+</sup> and Olig2<sup>+</sup> NPCs, but not in the ependymal cells lining the ventricles (Supplementary Fig. 4a,b). These findings indicate that *Bbs1* knockout in *Bbs1*<sup>CKO</sup> mice is specific to a particular class of periventricular NPCs in the cortex and hypothalamus. *Bbs1*<sup>CKO</sup> mice exhibit hydrocephalus with an onset at P3 in the absence of obstruction (Fig. 4a–d and Supplementary Fig. 4c,d). Moreover, neonatal hydrocephalus in *Bbs1*<sup>CKO</sup> mice was 100% penetrant. TUNEL and BrdU staining revealed a two-fold increase in apoptotic cells (Fig. 4e,f, **top**) and a 50% reduction in proliferating cells in *Bbs1*<sup>CKO</sup> mice relative to PDGFR $\alpha$ <sup>Cre</sup> mice (controls) (Fig. 4g,h, **top**). We found that nearly all TUNEL<sup>+</sup> and a majority of BrdU<sup>+</sup> cells in the SVZ in PDGFR $\alpha$ <sup>Cre</sup> and *Bbs1*<sup>CKO</sup> mice also stained positive for NG2 and PDGFR $\alpha$ , and to a lesser extent, Olig2 (Supplementary Fig. 5a,b). Quantitation revealed an approximately two-fold increase and 50% reduction in the number of TUNEL and BrdU labeled NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> cells respectively in *Bbs1*<sup>CKO</sup> brains relative to control brains (Fig. 4f,h, **bottom**). No significant differences were found in the number of Olig2 labeled cells undergoing apoptosis (TUNEL<sup>+</sup>,  $P=0.32$ ) or replication (BrdU<sup>+</sup>,  $P=0.22$ , Fig. 4f,h, **bottom**). These results demonstrate that the normal development of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs is disrupted following *Bbs1* knockout in this specific cell type. Moreover, these results confirm the involvement of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs in the development of normal cerebral ventricles, disruption of which results in neonatal hydrocephalus.

Finally, we investigated whether dysfunctional motile cilia could contribute to the dilated ventricles observed in *Bbs1*<sup>CKO</sup> brains. We examined the ultrastructure of motile cilia in PDGFR $\alpha$ <sup>Cre</sup> and *Bbs1*<sup>CKO</sup> brains at P14 and three months of age and found no abnormalities in the ultrastructure or number of tufts of motile cilia in the lateral ventricles of *Bbs1*<sup>CKO</sup> brains (Fig. 4i). This finding provides further evidence that hydrocephalus in BBS is caused by motile cilia-independent processes.

### **Bbs1 is required for PDGFR $\alpha$ signaling in NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> neural progenitor cells**

Next we examined cellular signaling pathways to assess the cause of impaired survival and proliferation of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs. We studied the PDGFR $\alpha$  signaling pathway because this pathway plays a major role in the survival and proliferation of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs<sup>36–40</sup>. We cultured primary OLPs from WT and *Bbs1*<sup>M390R/M390R</sup> neonates. Treatment of WT cultures with PDGF $\alpha$ , which specifically binds to PDGFR $\alpha$ , resulted in a large increase in the phosphorylation of PDGFR $\alpha$  and the two downstream effector proteins, AKT, master regulator of cell survival and proliferation and GSK3 $\beta$ , which regulates cell proliferation<sup>41–43</sup> (Fig. 5a). The specificity of the response to PDGF $\alpha$  in WT cultures was shown by pretreatment with the PDGFR inhibitor, AG1296, which reduced the response to PDGF $\alpha$ . *Bbs1*<sup>M390R/M390R</sup> derived OLP cultures showed a blunted phosphorylation response to PDGF $\alpha$  stimulation (Fig. 5a).

In order to confirm these findings *in vivo*, we infused PDGF $\alpha$  into the lateral ventricles of control and mutant mice for six days. All infused WT mice developed atypical hyperplasias in either the medial or lateral wall of the ipsilateral ventricle while none of the treated *Bbs1*<sup>M390R/M390R</sup> mice showed this response (Fig. 5b,c). Furthermore, the hyperplastic

nodules in WT infused brains contain a large proportion of small, round proliferating (BrdU<sup>+</sup>) cells (Fig. 5c,d). Immunostaining also identified a large increase in the population of PDGFR $\alpha$ <sup>+</sup> NPCs in the medial wall of the PDGF $\alpha$  infused lateral ventricle in WT mice but not in *Bbs1*<sup>M390R/M390R</sup> mice (Fig. 5d). These findings demonstrate that *Bbs1*<sup>M390R/M390R</sup> NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs do not respond to PDGF $\alpha$  and implicate a mechanism underlying the impaired survival and proliferation of NPCs in BBS. To study the role of BBS proteins in PDGFR $\alpha$  signaling we performed immunoprecipitation experiments. *In vitro* and *in vivo* experiments revealed that PDGFR $\alpha$  physically interacts with the BBSome (Supplementary Fig. 6a,b). These findings indicate a mechanism underlying the impaired PDGFR $\alpha$  signaling in BBS.

### Lithium therapy rescues hydrocephalus through a GSK3 $\beta$ dependent mechanism

We attempted to modify the neonatal hydrocephalic phenotype in *Bbs1*<sup>M390R/M390R</sup> mice during the critical perinatal period by targeting defective PDGFR $\alpha$  signaling and OLP development. Lithium has been shown to enhance proliferation and promote survival of NPCs by stimulating phosphorylation of two downstream effectors in the PDGFR $\alpha$  pathway, AKT and GSK3 $\beta$ <sup>44–46</sup>. We treated *Bbs1*<sup>M390R/M390R</sup> heterozygous pregnant females, which had been previously mated to heterozygous male mice, with lithium chloride (LiCl) or an equimolar NaCl solution, administered in drinking water beginning at E14.5 (Fig. 6a). Histological analysis of P14 WT and *Bbs1*<sup>M390R/M390R</sup> brains revealed that lithium treatment in WT mice has no significant effect (NaCl WT vs. LiCl WT,  $P=0.17$ ), whereas lithium treatment of *Bbs1*<sup>M390R/M390R</sup> mice ( $n=9$ ) results in an approximately 50% reduction in the cross sectional area of the lateral ventricles relative to NaCl treated *Bbs1*<sup>M390R/M390R</sup> mice ( $n=5$ ; Fig. 6a,b, **top** and **c, left**). Magnetic resonance imaging (MRI) at 3 months of age revealed that the ventricular volume of lithium treated WT mice does not differ from control treated WT mice ( $P=0.16$ , Fig. 6b, **bottom** and **c, right**). However, lithium treated *Bbs1*<sup>M390R/M390R</sup> mice show an approximately 50% reduction in ventricle volume relative to control treated *Bbs1*<sup>M390R/M390R</sup> mice (Fig. 6b, **bottom** and **c, right**). These effects of lithium were observed in all treated *Bbs1*<sup>M390R/M390R</sup> mice.

To study the mechanism underlying the lithium effect on neonatal hydrocephalus we examined cell proliferation and apoptosis in the periventricular regions of P3 mice using BrdU and TUNEL assays, respectively. Staining revealed that lithium has no significant effect on the number of proliferating or apoptotic cells in WT mice (NaCl WT vs. LiCl WT; BrdU,  $P=0.29$ ; TUNEL,  $P=0.21$ ; Fig. 6d–g). However, lithium treatment results in an approximately two-fold increase in proliferating cells in *Bbs1*<sup>M390R/M390R</sup> mice relative to NaCl treated *Bbs1*<sup>M390R/M390R</sup> (Fig. 6d,e, **left**). Importantly, there is no significant difference in the number of proliferating cells in NaCl treated WT and lithium treated *Bbs1*<sup>M390R/M390R</sup> mice indicating a complete rescue of the cell proliferation defect ( $P=0.16$ , Fig. 6d,e, **left**). There is also no significant difference in the number of apoptotic cells in NaCl and lithium treated *Bbs1*<sup>M390R/M390R</sup> mice indicating that the effect of lithium is specific to cell proliferation ( $P=0.29$ , Fig. 6f,g, **left**). Furthermore, lithium treatment specifically rescued NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPC proliferation but not apoptosis in *Bbs1*<sup>M390R/M390R</sup> mice (NaCl vs. LiCl *Bbs1*<sup>M394R/M394R</sup>, NG2<sup>+</sup>,  $P=0.36$ ; PDGFR $\alpha$ <sup>+</sup>,  $P=0.38$ ) (Fig. 6e,g, **right** and Supplementary Figs. 7 and 8). Lithium also increased the



number of proliferating Olig2<sup>+</sup> cells in WT and *Bbs1*<sup>M390R/M390R</sup> mice by more than two-fold (Fig. 6e, **right** and Supplementary Fig. 7).

To determine the molecular mechanisms underlying the effects of lithium, we examined the phosphorylation of AKT and GSK3 $\beta$ . Western blot analysis revealed that lithium treatment increases phosphorylation of GSK3 $\beta$  yet has no effect on the phosphorylation of AKT (Fig 6h). These results indicate that defective NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPC development leads to neonatal hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice. Targeting the defective PDGFR $\alpha$  signaling pathway in these NPCs rescues the proliferation of these cells resulting in a partial rescue of hydrocephalus.

## DISCUSSION

Hydrocephalus is a complex disorder involving both multiple genetic and environmental components<sup>3,4,9</sup>. Thus any single pathway or mechanism will not fully explain all of hydrocephalus. Previous studies implicate impaired ependymal motile cilia, CSF overproduction and cortical atrophy in the genesis of communicating hydrocephalus<sup>4,10,13–16,20,47</sup>. Here we demonstrate that NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs play a key role in the pathogenesis of hydrocephalus. We found that impaired PDGFR $\alpha$  signaling in *Bbs1*<sup>M390R/M390R</sup> mice leads to increased apoptosis and reduced proliferation of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs resulting in hydrocephalus. We have also demonstrated that dysfunctional motile cilia are not the primary cause of neonatal hydrocephalus in BBS mouse models as evidenced by ventricular dilation occurring prior to the development of motile cilia and that ependymal cilia remain intact in mice lacking *Bbs1* in PDGFR $\alpha$ <sup>+</sup> cells. We have not excluded the possibility that motile cilia defects may contribute to the severity of the phenotype in older *Bbs1*<sup>M390R/M390R</sup> mice. These findings steer the study of hydrocephalus beyond the ciliopathy field as evidenced by the common theme of abnormal cellular signaling in other models of hydrocephalus<sup>14–16,48–51</sup>.

Although we found that NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> cells exhibit impaired survival and proliferative capacities, we also found that Olig2<sup>+</sup> cells appear normal despite both cell types existing within the oligodendrocytic lineage. This finding suggests that *Bbs1* plays an essential role in the survival and proliferative capacities of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> cells but not Olig2<sup>+</sup> cells. The abnormal survival and proliferative capacities and the reduced populations of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs in periventricular regions may explain recent observations that BBS patients and mouse models have reduced white and gray matter volume in periventricular subcortical structures<sup>19,31,32</sup>. The MRI findings in patients suggest a loss of cerebral tissue as a cause of ventriculomegaly<sup>31,32</sup>. Our data indicate that the underlying cause of reduced cerebral tissue and ventricular dilation in BBS patients is due to impaired survival and proliferation of NPCs rather than degeneration of mature neurons and glia.

The impaired PDGFR $\alpha$  signaling in BBS led us to explore the therapeutic potential of targeting this pathway to modify the hydrocephalic phenotype early in development. We targeted two downstream effector proteins in the PDGFR $\alpha$  signaling cascade, AKT and GSK3 $\beta$ , using lithium, a drug that stimulates phosphorylation of these proteins<sup>44–46,52</sup>. Phosphorylation of AKT and GSK3 $\beta$  has been shown to increase cell survival and cell

proliferation<sup>41–43</sup>. We found that lithium treatment selectively rescues NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> cell proliferation by stimulating phosphorylation of GSK3 $\beta$  leading to a reduction in the size of the dilated ventricles in *Bbs1* mutant mice (Fig. 6h). These results are consistent with those of previous studies demonstrating that lithium stimulates NPC proliferation by increasing phosphorylation of GSK3 $\beta$  thereby suppressing its activity<sup>44–46,52</sup>. Although lithium rescues cell proliferation, it has no significant effect on cell death of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs. This finding may explain the partial rescue of the hydrocephalic phenotype. Rescue of both cell proliferation and apoptosis may result in a further reduction in ventricular size. To our knowledge, we are the first to target NPC development as a therapy to treat hydrocephalus in any model organism.

Finally, our results demonstrate that BBS proteins play a crucial role in PDGFR $\alpha$  signaling and NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPC development in the CNS. The trafficking function of the BBSome, is disrupted in BBS mutant mice<sup>30</sup>. As a result, signaling proteins are mislocalized leading to an abnormal cellular response in BBS mutant mice<sup>23,30,53,54</sup>. Our findings suggest that the aberrant PDGFR $\alpha$  signaling observed in *Bbs1*<sup>M390R/M390R</sup> mice originates from the mistrafficking of PDGFR $\alpha$  based on our observations that PDGFR $\alpha$  interacts with primary components of the BBSome and hence, is likely a novel cargo protein of the BBSome. However, the exact mechanism underlying the PDGFR $\alpha$  signaling defects in BBS remains to be elucidated.

By targeting GSK3 $\beta$  we rescued the development of NG2<sup>+</sup>PDGFR $\alpha$ <sup>+</sup> NPCs and hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice. The strategy of targeting downstream effectors of signaling defects may be applicable to other BBS-associated phenotypes.

## online Methods

### Animals

We used male and female mice on pure 129/SvEv genetic background for *Bbs1*<sup>M390R/M390R</sup> mice and littermate controls. We generated PDGFR $\alpha$ <sup>Cre</sup> (control) and *Bbs1*<sup>CKO</sup> mice by crossing *Bbs1*<sup>loxP/loxP</sup> (129/SvEv)  $\times$  *PDGFR $\alpha$* <sup>Cre</sup> (C57BL/6NJ) (Jackson Laboratory, Bar Harbor, Maine). We used littermate and aged matched controls for all animal experiments. Animals were generated at the University of Iowa Carver College of Medicine and all experiments were performed in accordance with the Institute for Animal Care and Use Committee at the University of Iowa (Iowa City, Iowa).

### Magnetic Resonance Imaging (MRI)

We obtained human T2-weighted MRI scans from K.M.K. and P.N. at the University of Iowa and Leslie Biesecker at the Clinical Research Center at the National Institutes of Health (NIH) in Bethesda, MD, USA. Informed consent was obtained for each human subject. Human subject research was approved by the by both the Institutional Review Board (IRB) of the National Human Genome Research Institute (NHGRI), at the National Institutes of Health (NIH), and by the IRB of the University of Iowa. For mice, we performed T2-weighted MRI scans while each mouse was under isoflurane induced anesthesia using a Varian Unity/Inova 4.7 T small-bore MRI system (Varian, Inc., Palo Alto, California) at the University of Iowa. There was an in-plane resolution of 0.13  $\times$  0.25



mm<sup>2</sup> and an approximate slice thickness of 0.6 mm acquired in the axial, sagittal, and coronal planes.

### **Histology, immunohistochemistry, BrdU and TUNEL assays**

We sectioned and stained mouse brains fixed by intracardiac perfusion with 4% paraformaldehyde at 7  $\mu$ m with hematoxylin and eosin. All mouse brains derived from fresh frozen tissue were cryosectioned (8  $\mu$ m sections). For BrdU experiments, we injected mice intraperitoneally with 300mg/kg BrdU (Sigma, St. Louis, Missouri), exposed for four hours then subsequently sacrificed. We double stained cryosections with either an antibody to BrdU (1:200, Abcam) or Click-iT TUNEL assay (Life Technologies, Grand Island, New York) according to the manufacturer's protocols and with the following antibodies: mouse Nestin (1:200; Abcam, Cambridge, Massachusetts), mouse O4 (1:200, Millipore), mouse NeuN (1:200, Millipore), rabbit GFAP (1:500, Abcam), rabbit NG2 (1:400, Millipore), rabbit PDGFR $\alpha$  (1:200, Santa Cruz Biotechnology Inc., Santa Cruz, California) and rabbit Olig2 (1:800, Abnova, Walnut, California). We blocked sections with 1% fetal calf serum (Life Technologies) plus 0.3% Triton X-100 (Sigma) in PBS for 1 hour at 25 °C, before primary antibody incubation at 4 °C overnight or at 25 °C for one hour. We used goat Alexa-Fluor secondary antibodies (Life Technologies) to image primary antigens and nuclei were counterstained with Vectashield containing DAPI (Vector Laboratories, Burlingame, California).

### **Cell Culture**

We cultured oligodendrocyte precursor cells (OLPs) from dissociated cortices of P0 mice. We dissociated cortices in trypsin using a P1000 pipette after which we added DMEM (Gibco, Grand Island, New York) supplemented with 20% fetal calf serum (FCS, Gibco) and 1% pen-strep (PS, Gibco). We then plated cells in T25 culture flasks (Corning) and cultured these cells for 7 days at which point cells were shaken overnight in 37°C at 250rpm to separate OLPs. At this point nearly all of the attached cells were astrocytes and the unattached cells were OLPs. Next we removed the media containing unattached OLPs and plated them on plastic culture dishes (Corning Inc., Corning, New York). We maintained all cells for an additional 2 days or until confluent using DMEM supplemented with 10% FCS and 1% PS. Prior to treatment, all cells were serum starved for 16 hours.

### **PDGF $\alpha$ treatment of cells and mice**

For receptor activation analysis *in vitro*, we treated cells with 50ng/mL PDGF $\alpha$  (Cell Signaling Technologies, Danvers, Massachusetts) for 10 minutes following pretreatment with 8 $\mu$ M AG1296 (Cayman Chemical Company, Ann Arbor, Michigan) for 30 minutes. For *in vivo* experiments we infused PDGF $\alpha$  (80ng/day) in vehicle (1mg/mL BSA/PBS) or vehicle alone into the lateral ventricle of 3MO mice for 6 days using a miniosmotic pump per manufacturer's instructions (Azlet).

### **Immunoprecipitation and western blotting**

We performed *in vitro* immunoprecipitations as previously described<sup>23</sup>. For endogenous immunoprecipitation experiments, we isolated brain cortices from P3 mice, lysed tissues in

RIPA buffer containing protease and phosphatase inhibitors (Roche Applied Science, Indianapolis, Indiana). and pre-cleared lysates with protein G beads (Thermo Fisher Scientific, Rockford, Illinois) overnight at 4 °C. We added a goat antibody to PDGFR $\alpha$  (1:100, R&D Systems, Minneapolis, Minnesota) and incubated overnight at 4 °C. We next incubated samples with protein G beads for 4 hours at 4 °C then washed briefly. We performed SDS-page and western blotting as described previously<sup>35</sup> using 10  $\mu$ g total protein per lane. We performed western blotting using the SuperSignal West Pico kit (Pierce Biotechnology, Rockford, Illinois) per manufacturer's instructions. We blocked membranes for one hour in TBST+5% milk or BSA then incubated overnight at 4°C with the following primary antibodies: mouse Flag (Sigma), mouse GFP (Santa Cruz), rabbit BBS2<sup>30</sup>, rabbit BBS4<sup>30</sup>, rabbit BBS8 (Sigma), rabbit BBS9 (Sigma), rabbit phospho-PDGFR $\alpha$  (Tyr720) (1:1000, Sigma), goat PDGFR $\alpha$  (1:5000) and the following antibodies from Cell Signaling Technologies: rabbit phospho-AKT (Ser473) (1:5000), rabbit AKT (1:1000), rabbit phospho-GSK3 $\beta$  (Ser9) (1:1000) and rabbit GSK3 $\beta$  (1:1000).

### qRT-PCR experiments

We sacrificed mice by CO<sub>2</sub> asphyxiation, and we excised four brain regions including cortex, hypothalamus, hippocampus and cerebellum. We extracted mRNA using Trizol reagent (Life Technologies). We performed Real-time RT-PCR to compare the mRNA levels of BBS1 between the control and BBS1 conditional knockout tissues. We used the following BBS1 primers: 5'-TTCTGCAGCTGGAGCTGAGTG-3' (forward), 5'-TCAGTGCCTAGCACAGACAG-3' (reverse); RPL19 was used as an internal control.

### Lithium therapy

We treated mice with lithium chloride (Sigma) in drinking water using a dose of 1.2 g/L starting from E14.5 (through pregnant and nursing dams). The drug was dissolved in double distilled water.

### Electron microscopy

We obtained scanning electron micrographs of the lateral wall of the lateral ventricles dissected from mice using a Hitachi S-4800 scanning electron microscope (Hitachi, Pleasanton, California). We also obtained transmission electron micrographs of choroid plexi using a Gatan UltraScan 1000 (Pleasanton, California) 2kx2k CCD digital camera.

### Dye injection and visualization of CSF flow

We anesthetized adult mice and injected Evans Blue dye into the lateral ventricles. The syringe was left in for 20 minutes to prevent CSF loss and to allow CSF to circulate. We then euthanized and cryopreserved mice at -20 °C. The next day, frozen heads were cut in the sagittal plane and imaged.

### CSF collection and analysis

We anesthetized adult mice and inserted a glass micropipette into the cisterna magna for CSF collection. We froze all collected samples at -20 °C until analysis. We measured the

chloride and sodium ion content using ion specific electrodes (Roche/Hitachi, Indianapolis, Indiana) in the Pathology Laboratory of the University of Iowa Hospitals and Clinics.

### Image analysis and statistics

We cropped all images and adjusted the brightness/contrast using Adobe Photoshop CS5. For immunofluorescent images, we adjusted the brightness/contrast using Zen Light. We performed all cell quantifications, cross-sectional area and volumetric analyses using ImageJ (NIH). We performed statistical comparisons using unpaired *t* tests. Mean values  $\pm$  standard error of the mean (s.e.m.) are reported.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

We thank Leslie Biesecker for help obtaining the human MRI scans. We thank Kamal Rahmouni and Deng-Fu Guo for help with qRT-PCR and infusion experiments. We thank Khristofor Agassandian for help with dye injection and CSF collection. We thank Valerie Buffard and Lan Qian for their excellent technical assistance. We also appreciate valuable assistance from the University of Iowa Central Microscopy Research Facility. This work was supported in part by National Institutes of Health Grants R01EY110298 and R01EY017168 (to V.C.S.) and the Neurosurgery Research and Education Foundation (to T.W.V.). C.S.C. is a National Science Foundation graduate research fellow and V.C.S. is an Investigator of the Howard Hughes Medical Institute.

This work has not been previously published in whole or in part or submitted elsewhere for review.

### References

1. Bruni JE, Del Bigio MR, Clattenburg RE. Ependyma: Normal and pathological. A review of the literature. *Brain Research Reviews*. 1985; 9:1–19.
2. Del Bigio M. Ependymal cells: biology and pathology. *Acta Neuropathologica*. 2010; 119:55–73. [PubMed: 20024659]
3. Williams MA, et al. Priorities for hydrocephalus research: report from a National Institutes of Health–sponsored workshop. *Journal of Neurosurgery: Pediatrics*. 2007; 107:345–357. [PubMed: 18459897]
4. Vogel P, et al. Congenital Hydrocephalus in Genetically Engineered Mice. *Veterinary Pathology Online*. 2012; 49:166–181.
5. Simon TD, et al. Hospital care for children with hydrocephalus in the United States: utilization, charges, comorbidities, and deaths. *Journal of Neurosurgery: Pediatrics*. 2008; 1:131–137. [PubMed: 18352782]
6. Shannon CN, et al. The economic impact of ventriculoperitoneal shunt failure. *Journal of Neurosurgery: Pediatrics*. 2011; 8:593–599. [PubMed: 22132918]
7. Van Camp G, et al. A duplication in the L1CAM gene associated with X-linked hydrocephalus. *Nature genetics*. 1993; 4:421–425. [PubMed: 8401593]
8. Chi JH, Fullerton HJ, Gupta N. Time trends and demographics of deaths from congenital hydrocephalus in children in the United States: National Center for Health Statistics data, 1979 to 1998. *Journal of neurosurgery*. 2005; 103:113–118. [PubMed: 16370275]
9. Zhang J, Williams MA, Rigamonti D. Genetics of human hydrocephalus. *Journal of neurology*. 2006; 253:1255–1266. [PubMed: 16773266]
10. Banizs B, et al. Dysfunctional cilia lead to altered ependyma and choroid plexus function, and result in the formation of hydrocephalus. *Development (Cambridge, England)*. 2005; 132:5329–5339.

11. Patwardhan RV, Nanda A. Implanted ventricular shunts in the United States: the billion-dollar-a-year cost of hydrocephalus treatment. *Neurosurgery*. 2005; 56:139–144. discussion 144-135. [PubMed: 15617596]
12. Vogel TW, Carter CS, Abode-Iyamah K, Zhang Q, Robinson S. The role of primary cilia in the pathophysiology of neural tube defects. *Neurosurgical Focus*. 2012; 33:E2. [PubMed: 23025443]
13. Spassky N, et al. Adult ependymal cells are postmitotic and are derived from radial glial cells during embryogenesis. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2005; 25:10–18. [PubMed: 15634762]
14. Tissir F, et al. Lack of cadherins *Celsr2* and *Celsr3* impairs ependymal ciliogenesis, leading to fatal hydrocephalus. *Nature neuroscience*. 2010; 13:700–707. [PubMed: 20473291]
15. Talos F, et al. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. *Cell death and differentiation*. 2010; 17:1816–1829. [PubMed: 21076477]
16. Yang A, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. *Nature*. 2000; 404:99–103. [PubMed: 10716451]
17. Drake JM. The surgical management of pediatric hydrocephalus. *Neurosurgery*. 2008; 62(Suppl 2): 633–640. discussion 640-632. [PubMed: 18596441]
18. Drake JM, Kestle JR, Tuli S. CSF shunts 50 years on--past, present and future. *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery*. 2000; 16:800–804.
19. Davis RE, et al. A knockin mouse model of the Bardet-Biedl syndrome 1 M390R mutation has cilia defects, ventriculomegaly, retinopathy, and obesity. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:19422–19427. [PubMed: 18032602]
20. Ibanez-Tallon I, et al. Dysfunction of axonemal dynein heavy chain *Mdnah5* inhibits ependymal flow and reveals a novel mechanism for hydrocephalus formation. *Human molecular genetics*. 2004; 13:2133–2141. [PubMed: 15269178]
21. Lancaster MA, Schroth J, Gleeson JG. Subcellular spatial regulation of canonical Wnt signalling at the primary cilium. *Nature cell biology*. 2011; 13:700–707. [PubMed: 21602792]
22. Ocbina PJ, Eggenschwiler JT, Moskowicz I, Anderson KV. Complex interactions between genes controlling trafficking in primary cilia. *Nature genetics*. 2011; 43:547–553. [PubMed: 21552265]
23. Zhang Q, Seo S, Bugge K, Stone EM, Sheffield VC. BBS proteins interact genetically with the IFT pathway to influence SHH-related phenotypes. *Human molecular genetics*. 2012; 21:1945–1953. [PubMed: 22228099]
24. Schneider L, et al. PDGFR $\alpha$  signaling is regulated through the primary cilium in fibroblasts. *Current biology : CB*. 2005; 15:1861–1866. [PubMed: 16243034]
25. Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. *Annual review of neuroscience*. 2009; 32:149–184.
26. Han YG, et al. Hedgehog signaling and primary cilia are required for the formation of adult neural stem cells. *Nature neuroscience*. 2008; 11:277–284. [PubMed: 18297065]
27. Breunig JJ, et al. Primary cilia regulate hippocampal neurogenesis by mediating sonic hedgehog signaling. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105:13127–13132. [PubMed: 18728187]
28. Sawamoto K, et al. New neurons follow the flow of cerebrospinal fluid in the adult brain. *Science (New York, N.Y.)*. 2006; 311:629–632.
29. Ihrie RA, Alvarez-Buylla A. Lake-front property: a unique germinal niche by the lateral ventricles of the adult brain. *Neuron*. 2011; 70:674–686. [PubMed: 21609824]
30. Nachury MV, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. *Cell*. 2007; 129:1201–1213. [PubMed: 17574030]
31. Baker K, et al. Neocortical and hippocampal volume loss in a human ciliopathy: A quantitative MRI study in Bardet-Biedl syndrome. *American journal of medical genetics. Part A*. 2011; 155A: 1–8. [PubMed: 21204204]
32. Keppler-Noreuil KM, et al. Brain tissue- and region-specific abnormalities on volumetric MRI scans in 21 patients with Bardet-Biedl syndrome (BBS). *BMC medical genetics*. 2011; 12:101. [PubMed: 21794117]

33. von Bohlen Und Halbach O. Immunohistological markers for staging neurogenesis in adult hippocampus. *Cell and tissue research*. 2007; 329:409–420. [PubMed: 17541643]
34. Raponi E, et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. *Glia*. 2007; 55:165–177. [PubMed: 17078026]
35. Jackson EL, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. *Neuron*. 2006; 51:187–199. [PubMed: 16846854]
36. Rivers LE, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. *Nature neuroscience*. 2008; 11:1392–1401. [PubMed: 18849983]
37. Richardson WD, Young KM, Tripathi RB, McKenzie I. NG2-glia as multipotent neural stem cells: fact or fantasy? *Neuron*. 2011; 70:661–673. [PubMed: 21609823]
38. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2010; 30:16383–16390. [PubMed: 21123584]
39. Nishiyama A, Komitova M, Suzuki R, Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. *Nature reviews. Neuroscience*. 2009; 10:9–22. [PubMed: 19096367]
40. Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. *Science (New York, N.Y.)*. 2000; 289:1754–1757.
41. Datta SR, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell*. 1997; 91:231–241. [PubMed: 9346240]
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nature reviews. Cancer*. 2002; 2:489–501. [PubMed: 12094235]
43. Scheid MP, Woodgett JR. PKB/AKT: functional insights from genetic models. *Nature reviews. Molecular cell biology*. 2001; 2:760–768. [PubMed: 11584303]
44. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. *Proceedings of the National Academy of Sciences of the United States of America*. 1999; 96:8745–8750. [PubMed: 10411946]
45. Su H, Chu TH, Wu W. Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord. *Experimental neurology*. 2007; 206:296–307. [PubMed: 17599835]
46. Li H, et al. Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. 2011; 31:2106–2115.
47. Lechtreck KF, Delmotte P, Robinson ML, Sanderson MJ, Witman GB. Mutations in Hydin impair ciliary motility in mice. *The Journal of cell biology*. 2008; 180:633–643. [PubMed: 18250199]
48. Goto J, Tezuka T, Nakazawa T, Sagara H, Yamamoto T. Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development. *Molecular and cellular neurosciences*. 2008; 38:203–212. [PubMed: 18403215]
49. Qin S, Liu M, Niu W, Zhang CL. Dysregulation of Kruppel-like factor 4 during brain development leads to hydrocephalus in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:21117–21121. [PubMed: 22160720]
50. Yung YC, et al. Lysophosphatidic acid signaling may initiate fetal hydrocephalus. *Science translational medicine*. 2011; 3:99ra87.
51. Riviere JB, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nature genetics*. 2012; 44:934–940. [PubMed: 22729224]
52. Azim K, Butt AM. GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo. *Glia*. 2011; 59:540–553. [PubMed: 21319221]
53. Berbari NF, Lewis JS, Bishop GA, Askwith CC, Mykytyn K. Bardet-Biedl syndrome proteins are required for the localization of G protein-coupled receptors to primary cilia. *Proceedings of the*

National Academy of Sciences of the United States of America. 2008; 105:4242–4246. [PubMed: 18334641]

54. Seo S, et al. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. *Human molecular genetics*. 2009; 18:1323–1331. [PubMed: 19150989]


Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Figure 1.**

Hydrocephalus in BBS mutant mice occurs before motile cilia develop. **(a)** T2-weighted coronal MRIs of a Bardet-Biedl syndrome patient and age and sex matched control showing ventriculomegaly of the lateral ventricles (red asterisks). **(b)** Left, picture of 3 month old WT and *Bbs1*<sup>M390R/M390R</sup> mice showing a normal cranial vault in WT and *Bbs1*<sup>M390R/M390R</sup>. Right, T2-weighted sagittal MRIs showing hydrocephalus of the lateral ventricles (red asterisks) in a *Bbs1*<sup>M390R/M390R</sup> mouse. **(c)** Histology of WT and *Bbs1*<sup>M390R/M390R</sup> neonates showing perinatal onset of hydrocephalus in mutant pups and **(d)** the quantitations showing ventricular dilation at P3 and P7. **(e)** Timeline of the genesis of hydrocephalus in BBS mutant mice relative to motile cilia development showing that *Bbs1*<sup>M390R/M390R</sup> mice develop hydrocephalus prior to the development of motile cilia<sup>13,14</sup>. All error bars represent means  $\pm$  s.e.m. \* $P < 0.05$ , \*\*\* $P < 0.0005$ , results from unpaired *t* tests. All experiments utilized at least 3 mice per group and genotype. Scale bars equal 1 mm **(b)** and 500  $\mu$ m (P0 and P3) and 1 mm (P7, **c**). E, embryonic day; LV, lateral ventricle; P, postnatal day.


**Figure 2.**

Increased apoptosis and reduced proliferation in the brains of *Bbs1*<sup>M390R/M390R</sup> mice. Top left, cartoon depicting the sagittal section of a mouse brain showing the region of subsequent analyses (R1). (a) Representative immunofluorescent images and (b) the quantitation of cells labeled with TUNEL (top row) or BrdU (bottom row) per area in P3 and P7 WT and *Bbs1*<sup>M390R/M390R</sup> brains in at least 3 mice per group and genotype (dotted yellow line outlines SVZ). All error bars represent means  $\pm$  s.e.m. \* $P < 0.05$ , \*\* $P < 0.005$ , \*\*\* $P < 0.0005$ , results from unpaired *t* tests. Scale bars equal 100  $\mu$ m (a, top) and 50  $\mu$ m (bottom). CPu, caudate putamen; LV, lateral ventricle; NS, not significant; *P*, postnatal day; SVZ, subventricular zone.




**Figure 3.** Abnormal development of NG2<sup>+</sup>PDGFRα<sup>+</sup> neural progenitor cells in *Bbs1*<sup>M390R/M390R</sup> mice. **(a,b)** Representative immunofluorescent images showing TUNEL **(a)** and BrdU **(b)** labeled cells also expressing NG2, PDGFRα or Olig2 plus the quantitations **(a,b)**, right). At least 3 mice per group and genotype were analyzed. All dotted yellow lines outline the SVZ. All error bars represent means ± s.e.m. \**P*<0.05, results from unpaired *t* tests. Scale bars equal 50 μm. CPu, caudate putamen; LV, lateral ventricle; NS, not significant; *P*, postnatal day; SVZ, subventricular zone.






**Figure 4.** Conditional knockout of *Bbs1* in NG2 $^+$ PDGFR $\alpha$  $^+$  progenitors causes neonatal hydrocephalus. **(a,b)** Representative histology of P3 PDGFR $\alpha$  $^{Cre}$  (control) ( $n=3$ ) and *Bbs1* $^{CKO}$  ( $n=3$ ) pups and the quantitations showing dilated lateral ventricles of *Bbs1* $^{CKO}$  mice (red asterisks). **(c,d)** Representative T2-weighted MRIs of 3 month old PDGFR $\alpha$  $^{Cre}$  ( $n=3$ ) and *Bbs1* $^{CKO}$  ( $n=3$ ) mice and the quantitations showing dilated ventricles in *Bbs1* $^{CKO}$  mice (red asterisks). **(e-h)** Representative immunofluorescent images and the quantitations of cells labeled with TUNEL **(e,f)** or BrdU **(g,h)** per area in P3 PDGFR $\alpha$  $^{Cre}$  ( $n=3$ ) and *Bbs1* $^{CKO}$  ( $n=3$ ) brains (yellow dotted line outlines SVZ). **(f,h, bottom)** Quantifications of TUNEL **(f, bottom)** and BrdU **(h, bottom)** labeled cells that also express NG2, PDGFR $\alpha$  or Olig2 (at least 3 mice per group and genotype). **(i)** Scanning electron micrographs of the lateral wall of the lateral ventricles in PDGFR $\alpha$  $^{Cre}$  and *Bbs1* $^{CKO}$  mice at low (left) and high (right) magnification. All error bars represent means  $\pm$  s.e.m. \* $P$ <0.05, \*\* $P$ <0.005,

\*\*\* $P < 0.0005$ , results from unpaired  $t$  tests. Scale bars equal 500  $\mu\text{m}$  (a), 1 mm (c), 100  $\mu\text{m}$  (e), 50  $\mu\text{m}$  (g), 20  $\mu\text{m}$  (left) and 4  $\mu\text{m}$  (right, i). CPu, caudate putamen; CKO, conditional knockout; LV, lateral ventricle; NS, not significant; P, postnatal day; SVZ, subventricular zone.



**Figure 5.** PDGFR $\alpha$  signaling is impaired in BBS. **(a)** PDGF $\alpha$  stimulation activates downstream signaling in primary oligodendrocytic precursor cells derived from WT but not *Bbs1*<sup>M390R/M390R</sup> brains. **(b)** Cartoon depicting the sagittal section of a mouse brain showing the cannula implantation site (solid red line) and the region of subsequent analyses (R1). **(c)** Representative histology of the ipsilateral brain hemisphere of vehicle infused WT ( $n=7$ ) and *Bbs1* KI ( $n=7$ ); and PDGF $\alpha$  infused WT ( $n=7$ ) and *Bbs1*<sup>M390R/M390R</sup> ( $n=7$ ) mice (bottom). White panels show a low magnification image with the region of interest outlined by the yellow dotted line. **(d)** Representative immunofluorescent images of the ipsilateral infused hemisphere showing cells labeled with BrdU and PDGFR $\alpha$  in vehicle infused WT ( $n=3$ ) and *Bbs1*<sup>M390R/M390R</sup> ( $n=3$ ); and PDGF $\alpha$  infused WT ( $n=3$ ) and *Bbs1*<sup>M390R/M390R</sup> ( $n=3$ ) mice. The yellow arrow highlights the hyperplastic nodule consisting of PDGFR $\alpha$ <sup>+</sup> cells and the white dotted line outlines the hyperplastic nodules observed in PDGF $\alpha$  infused WT mice. Scale bars equal 100  $\mu$ m (larger image) and 500  $\mu$ m (c, inset) and 100  $\mu$ m (larger image) and 500  $\mu$ m (d, inset).



**Figure 6.**

Lithium therapy rescues cell proliferation and hydrocephalus in *Bbs1*<sup>M390R/M390R</sup> mice. **(a)** Overview of the experimental timeframe. **(b)** Top row, representative histology plus quantitation (**c**, left) and representative MRI scans (bottom row) plus quantitation (**c**, right) of NaCl and LiCl treated WT and *Bbs1*<sup>M390R/M390R</sup> mice. Red asterisks highlight dilated lateral ventricles and yellow asterisks highlight reduced ventricle size following LiCl treatment in *Bbs1*<sup>M390R/M390R</sup> mice. **(d,e)** Representative immunofluorescent images of BrdU labeled cells in NaCl and LiCl treated mice (**d**) and quantitations (**e**, left). **(e)** Right, quantitation of BrdU labeled cells that also express NG2, PDGFRα or Olig2. **(f,g)** Representative immunofluorescent images (**f**) and quantitation (**g**, left) of TUNEL labeled cells in NaCl and LiCl treated mice. **(g)** Right, quantitation of TUNEL labeled cells expressing NG2, PDGFRα or Olig2. **(h)** Left, representative western blots of cortices from P3 NaCl and LiCl treated WT and *Bbs1*<sup>M390R/M390R</sup> mice. Right, drawing depicting the proposed mechanism of lithium's effect on cell proliferation in treated WT and *Bbs1*<sup>M390R/M390R</sup> mice. Lithium increases phosphorylation of GSK3β leading to an increase in cell proliferation. We found no effect on the phosphorylation of AKT in contrast to previously reported results<sup>44</sup>. Error bars represent means ± s.e.m. \**P*<0.05, \*\**P*<0.005, \*\*\**P*<0.0005, results from unpaired *t* tests. All experiments utilized 3 mice per group and

genotype. Scale bars equal 500  $\mu\text{m}$  (top, **b**) and 1 mm (bottom, **b**), 50  $\mu\text{m}$  (**d**) and 100  $\mu\text{m}$  (**f**). CPu, caudate putamen; E, embryonic day; LV, lateral ventricle; NS, not significant; P, postnatal day; SVZ, subventricular zone.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript